Founded in 1920, Dehns is one of Europe’s largest full service intellectual property firms, with offices in London, Munich, Oslo, Oxford, Bristol, Brighton, Manchester and Birmingham.
In addition to obtaining patent, trade mark and design protection around the world, our services also extend to IP management consulting and dispute resolution. Dehns attorneys have expertise in a wide range of technologies across the engineering, chemistry and biotechnology sectors.
Our clients include private inventors, universities and research institutions, start-ups and SMEs as well as large multinational corporations. We are firmly focussed on delivering clear advice and valuable results at a competitive cost.
Dehns’ straightforward, business-oriented approach combined with technical excellence has made us leaders in our field and we are proud of our top tier rankings.
This webinar, jointly hosted on 23 July 2020, covers the
patentability of diagnostic inventions in Europe, Canada and the
US.
In the webinar, patent attorneys from Dehns (Europe), Bereskin
& Parr (Canada) and Casimir Jones SC (US) provide practical
tips on how to overcome objections commonly raised in each of their
jurisdictions in the field of diagnostic inventions, with a focus
on excluded subject-matter objections, particularly objections
under 35 U.S.C. § 101.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
